Literature DB >> 19322943

Involvement of erythropoietin in retinal ischemic preconditioning.

John C Dreixler1, Sarah Hagevik, Jonathan W Hemmert, Afzhal R Shaikh, Daniel M Rosenbaum, Steven Roth.   

Abstract

BACKGROUND: The purpose of this study was to examine the role of erythropoietin in retinal ischemic preconditioning (IPC).
METHODS: Rats were subjected to retinal ischemia after IPC. Electroretinography assessed functional recovery after ischemia; retinal sections were examined to determine loss of retinal ganglion cells, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling was used to assess apoptosis. Levels of downstream mediators were measured in retinal homogenates by Western blotting. To assess the involvement of erythropoietin in IPC, Western blotting was used to measure levels of erythropoietin and its receptor (EPO-R) in retinal homogenates after IPC. To examine erythropoietin's role in IPC, the impact of blocking erythropoietin via intravitreal injection of soluble EPO-R (sEPO-R) before IPC was studied.
RESULTS: Erythropoietin levels did not change after IPC, but EPO-R increased. Intravitreal injection of sEPO-R significantly attenuated both the functional and histologic neuroprotection produced by IPC in comparison to control injection of denatured sEPO-R. Apoptotic damage after ischemia was enhanced in the sEPO-R-treated retinas as indicated by fluorescent terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Phosphorylated extracellular-signal-regulated kinase and heat shock protein 27, but not protein kinase B, upregulated in denatured sEPO-R-treated retinae, were attenuated in eyes injected with sEPO-R.
CONCLUSIONS: These results indicate that EPO-R upregulation is a critical component of the functional, histologic, and antiapoptotic protective effect of IPC on ischemia in the retina and that several downstream effectors may be involved in the neuroprotective actions of erythropoietin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322943      PMCID: PMC2891304          DOI: 10.1097/ALN.0b013e31819c4601

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  30 in total

1.  Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats.

Authors:  N Andrew Whitlock; Neeraj Agarwal; Jian-Xing Ma; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-03       Impact factor: 4.799

2.  A potential role for erythropoietin in focal permanent cerebral ischemia in mice.

Authors:  M Bernaudin; H H Marti; S Roussel; D Divoux; A Nouvelot; E T MacKenzie; E Petit
Journal:  J Cereb Blood Flow Metab       Date:  1999-06       Impact factor: 6.200

3.  Retinal ischemic preconditioning in the rat: requirement for adenosine and repetitive induction.

Authors:  B Li; S Roth
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-05       Impact factor: 4.799

4.  Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.

Authors:  Daisuke Watanabe; Kiyoshi Suzuma; Shigeyuki Matsui; Masafumi Kurimoto; Junichi Kiryu; Mihori Kita; Izumi Suzuma; Hirokazu Ohashi; Tomonari Ojima; Tomoaki Murakami; Toshihiro Kobayashi; Seiji Masuda; Masaya Nagao; Nagahisa Yoshimura; Hitoshi Takagi
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

5.  Preconditioning provides complete protection against retinal ischemic injury in rats.

Authors:  S Roth; B Li; P S Rosenbaum; H Gupta; I M Goldstein; K M Maxwell; J M Gidday
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-04       Impact factor: 4.799

6.  Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2.

Authors:  Ulkan Kilic; Ertugrul Kilic; Jorge Soliz; Claudio I Bassetti; Max Gassmann; Dirk M Hermann
Journal:  FASEB J       Date:  2004-11-19       Impact factor: 5.191

7.  Permanent focal cerebral ischemia activates erythropoietin receptor in the neonatal rat brain.

Authors:  Tong-Chun Wen; Marta Rogido; Tom Genetta; Augusto Sola
Journal:  Neurosci Lett       Date:  2004-01-30       Impact factor: 3.046

8.  Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model.

Authors:  Yun Sun; Changman Zhou; Paula Polk; Anil Nanda; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2004-02       Impact factor: 6.200

9.  Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration.

Authors:  Christian Grimm; Andreas Wenzel; Dinu Stanescu; Marijana Samardzija; Svenja Hotop; Mathias Groszer; Muna Naash; Max Gassmann; Charlotte Remé
Journal:  J Neurosci       Date:  2004-06-23       Impact factor: 6.167

10.  Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration.

Authors:  Tonia S Rex; Mariacarmela Allocca; Luciano Domenici; Enrico M Surace; Albert M Maguire; Arkady Lyubarsky; Alessandro Cellerino; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

View more
  15 in total

1.  Mitogen-activated protein kinase phosphatase-1 (MKP-1) in retinal ischemic preconditioning.

Authors:  John C Dreixler; Anthony Bratton; Eugenie Du; Afzhal R Shaikh; Brian Savoie; Michael Alexander; Marcus M Marcet; Steven Roth
Journal:  Exp Eye Res       Date:  2010-11-20       Impact factor: 3.467

2.  Adaptive Plasticity in the Retina: Protection Against Acute Injury and Neurodegenerative Disease by Conditioning Stimuli.

Authors:  Jeffrey M Gidday
Journal:  Cond Med       Date:  2018-02-15

3.  Post-ischemic conditioning in the rat retina is dependent upon ischemia duration and is not additive with ischemic pre-conditioning.

Authors:  John C Dreixler; Afzhal R Shaikh; Michael Alexander; Brian Savoie; Steven Roth
Journal:  Exp Eye Res       Date:  2010-06-23       Impact factor: 3.467

4.  Protein kinase B (Akt) and mitogen-activated protein kinase p38α in retinal ischemic post-conditioning.

Authors:  John C Dreixler; Ajay Sampat; Afzhal R Shaikh; Michael Alexander; Marcus M Marcet; Steven Roth
Journal:  J Mol Neurosci       Date:  2011-05-15       Impact factor: 3.444

5.  Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy.

Authors:  Freya M Mowat; Francisco Gonzalez; Ulrich F O Luhmann; Clemens A Lange; Yanai Duran; Alexander J Smith; Patrick H Maxwell; Robin R Ali; James W B Bainbridge
Journal:  Am J Pathol       Date:  2012-02-17       Impact factor: 4.307

6.  Delayed post-ischemic conditioning significantly improves the outcome after retinal ischemia.

Authors:  John C Dreixler; Jacqueline N Poston; Afzhal R Shaikh; Michael Alexander; Kelsey Y Tupper; Marcus M Marcet; Myriam Bernaudin; Steven Roth
Journal:  Exp Eye Res       Date:  2011-04-09       Impact factor: 3.467

Review 7.  Novel neuroprotective strategies in ischemic retinal lesions.

Authors:  Krisztina Szabadfi; Laszlo Mester; Dora Reglodi; Peter Kiss; Norbert Babai; Boglarka Racz; Krisztina Kovacs; Aliz Szabo; Andrea Tamas; Robert Gabriel; Tamas Atlasz
Journal:  Int J Mol Sci       Date:  2010-02-03       Impact factor: 6.208

Review 8.  The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy.

Authors:  Rafael Simó; Marta Villarroel; Lídia Corraliza; Cristina Hernández; Marta Garcia-Ramírez
Journal:  J Biomed Biotechnol       Date:  2010-02-17

9.  Mitogen-activated protein kinase p38alpha and retinal ischemic preconditioning.

Authors:  John C Dreixler; Frank C Barone; Afzhal R Shaikh; Eugenie Du; Steven Roth
Journal:  Exp Eye Res       Date:  2009-07-24       Impact factor: 3.467

10.  Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats.

Authors:  John C Dreixler; Jacqueline N Poston; Irina Balyasnikova; Afzhal R Shaikh; Kelsey Y Tupper; Sineadh Conway; Venkat Boddapati; Marcus M Marcet; Maciej S Lesniak; Steven Roth
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-03       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.